Sci Rep:下一代抗疟疾药物-二茂铁氯喹具有抗肿瘤活性

2017-11-25 AlexYang MedSci原创

尽管医学上发生了巨大的进步,癌症仍旧是全球健康最为严重的问题之一,并且还在等待新的有效药物治疗的出现。最近,有研究人员展示了二茂铁氯喹(FQ),下一代的抗疟疾药物,可以作为一种非常有希望的癌症药物治疗的候选者。研究发现,FQ在体内能够有效的抑制自我吞噬,扰乱溶酶体的功能以及损伤前列腺肿瘤生长。FQ还能够负调控Akt激酶和神经元低氧诱导因子(HIF-1α),并且在饥饿和缺氧条件下,在晚期固体肿瘤中F

尽管医学上发生了巨大的进步,癌症仍旧是全球健康最为严重的问题之一,并且还在等待新的有效药物治疗的出现。最近,有研究人员展示了二茂铁氯喹(FQ),下一代的抗疟疾药物,可以作为一种非常有希望的癌症药物治疗的候选者。

研究发现,FQ在体内能够有效的抑制自我吞噬,扰乱溶酶体的功能以及损伤前列腺肿瘤生长。FQ还能够负调控Akt激酶和神经元低氧诱导因子(HIF-1α),并且在饥饿和缺氧条件下,在晚期固体肿瘤中FQ尤其有效。另外,FQ能够增强几种化疗药物的抗癌活性,表明了它可作为一种现存抗癌治疗辅助药物的潜在应用。与它的母体化合物复合氯喹(CQ)相似的是,FQ能够在溶酶体中积累并且使溶酶体脱酸化。更进一步的是,FQ能够诱导溶酶体膜透化作用、线粒体去极化和独立于半胱天冬酶的癌细胞死亡。总之,研究人员指出,他们的工作鉴定了二茂铁氯喹可作为一种很有希望的药物,并且具有很有效的抗癌活性。

原始出处:

Artem Kondratskyi, Kateryna Kondratska, Fabien Vanden Abeele et al. Ferroquine, the next generation antimalarial drug, has antitumor activity. Sci Rep. 21 Nov 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674947, encodeId=de3416e4947f4, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Oct 06 18:14:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998494, encodeId=b7b81998494e9, content=<a href='/topic/show?id=1f6755455d8' target=_blank style='color:#2F92EE;'>#抗疟疾药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55455, encryptionId=1f6755455d8, topicName=抗疟疾药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Wed Jan 03 02:14:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743788, encodeId=17771e43788aa, content=<a href='/topic/show?id=7efd5545308' target=_blank style='color:#2F92EE;'>#抗疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55453, encryptionId=7efd5545308, topicName=抗疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e01d35226644, createdName=zhangying8800, createdTime=Mon Dec 04 17:14:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034525, encodeId=a583203452574, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Nov 06 09:14:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264334, encodeId=2e85264334fa, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sun Nov 26 05:21:10 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264292, encodeId=c0d726429266, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Nov 25 22:22:38 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674947, encodeId=de3416e4947f4, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Oct 06 18:14:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998494, encodeId=b7b81998494e9, content=<a href='/topic/show?id=1f6755455d8' target=_blank style='color:#2F92EE;'>#抗疟疾药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55455, encryptionId=1f6755455d8, topicName=抗疟疾药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Wed Jan 03 02:14:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743788, encodeId=17771e43788aa, content=<a href='/topic/show?id=7efd5545308' target=_blank style='color:#2F92EE;'>#抗疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55453, encryptionId=7efd5545308, topicName=抗疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e01d35226644, createdName=zhangying8800, createdTime=Mon Dec 04 17:14:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034525, encodeId=a583203452574, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Nov 06 09:14:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264334, encodeId=2e85264334fa, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sun Nov 26 05:21:10 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264292, encodeId=c0d726429266, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Nov 25 22:22:38 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674947, encodeId=de3416e4947f4, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Oct 06 18:14:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998494, encodeId=b7b81998494e9, content=<a href='/topic/show?id=1f6755455d8' target=_blank style='color:#2F92EE;'>#抗疟疾药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55455, encryptionId=1f6755455d8, topicName=抗疟疾药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Wed Jan 03 02:14:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743788, encodeId=17771e43788aa, content=<a href='/topic/show?id=7efd5545308' target=_blank style='color:#2F92EE;'>#抗疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55453, encryptionId=7efd5545308, topicName=抗疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e01d35226644, createdName=zhangying8800, createdTime=Mon Dec 04 17:14:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034525, encodeId=a583203452574, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Nov 06 09:14:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264334, encodeId=2e85264334fa, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sun Nov 26 05:21:10 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264292, encodeId=c0d726429266, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Nov 25 22:22:38 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674947, encodeId=de3416e4947f4, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Oct 06 18:14:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998494, encodeId=b7b81998494e9, content=<a href='/topic/show?id=1f6755455d8' target=_blank style='color:#2F92EE;'>#抗疟疾药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55455, encryptionId=1f6755455d8, topicName=抗疟疾药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Wed Jan 03 02:14:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743788, encodeId=17771e43788aa, content=<a href='/topic/show?id=7efd5545308' target=_blank style='color:#2F92EE;'>#抗疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55453, encryptionId=7efd5545308, topicName=抗疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e01d35226644, createdName=zhangying8800, createdTime=Mon Dec 04 17:14:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034525, encodeId=a583203452574, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Nov 06 09:14:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264334, encodeId=2e85264334fa, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sun Nov 26 05:21:10 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264292, encodeId=c0d726429266, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Nov 25 22:22:38 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1674947, encodeId=de3416e4947f4, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Oct 06 18:14:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998494, encodeId=b7b81998494e9, content=<a href='/topic/show?id=1f6755455d8' target=_blank style='color:#2F92EE;'>#抗疟疾药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55455, encryptionId=1f6755455d8, topicName=抗疟疾药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Wed Jan 03 02:14:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743788, encodeId=17771e43788aa, content=<a href='/topic/show?id=7efd5545308' target=_blank style='color:#2F92EE;'>#抗疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55453, encryptionId=7efd5545308, topicName=抗疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e01d35226644, createdName=zhangying8800, createdTime=Mon Dec 04 17:14:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034525, encodeId=a583203452574, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Nov 06 09:14:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264334, encodeId=2e85264334fa, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sun Nov 26 05:21:10 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264292, encodeId=c0d726429266, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Nov 25 22:22:38 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
    2017-11-26 卡圣

    学习了.谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1674947, encodeId=de3416e4947f4, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Oct 06 18:14:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998494, encodeId=b7b81998494e9, content=<a href='/topic/show?id=1f6755455d8' target=_blank style='color:#2F92EE;'>#抗疟疾药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55455, encryptionId=1f6755455d8, topicName=抗疟疾药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Wed Jan 03 02:14:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743788, encodeId=17771e43788aa, content=<a href='/topic/show?id=7efd5545308' target=_blank style='color:#2F92EE;'>#抗疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55453, encryptionId=7efd5545308, topicName=抗疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e01d35226644, createdName=zhangying8800, createdTime=Mon Dec 04 17:14:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034525, encodeId=a583203452574, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Nov 06 09:14:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264334, encodeId=2e85264334fa, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sun Nov 26 05:21:10 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264292, encodeId=c0d726429266, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Nov 25 22:22:38 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
    2017-11-25 131****2916

    不错的文章值得推荐

    0

相关资讯

CLIN CANCER RES:通过FOXM1通路阻滞靶向前列腺癌亚型1

最近根据特殊的通路活化以及临床侵袭性将前列腺癌分为三个临床相关亚型(PCS)。其中PCS1是侵袭性最强最致命的亚型,在临床上尚无有效的治疗手段。CLIN CANCER RES近期发表了一篇文章,研究PCS1的分子靶标和治疗方法。

Sci Rep:前列腺癌中,谷氨酰胺利用率代谢差异能够导致代谢缺陷

新肿瘤精准医疗范例关注于鉴定代谢的、蛋白组学的、转录组学的和基因组学在肿瘤中的变化,以期能从这些变化中来调整治疗方案和改善病人治疗结果。代谢的变化是癌症的一种标志,并且代谢通路的抑制是目前靶向治疗癌症化学疗法的一种主要策略。然而,用来对代谢亚型分类的非侵入性生物标记还存在不足现象。最近,有研究人员进行旨在鉴定4中前列腺癌细胞系且具有不同程度恶化的细胞内和细胞外代谢情况的研究。研究人员调查了恶性前列

Sci Rep:通过治疗性超声传输编码肿瘤抑制子Sef的基因到前列腺癌肿瘤中可以同时抑制肿瘤血管生成和生长

恶性肿瘤占据了人类癌症类型的80%以上,并且到目前为止没有有效的治疗方法来控制转移性疾病。最近,有研究人员首次阐释了在体内试验中,治疗性超声(TUS)传输人类肿瘤抑制基因hSef-b到前列腺肿瘤中的效果。Sef在各种人类恶性肿瘤中表达均下调,并且与肿瘤的恶化相关。在体外试验中,hSef-b能够分别抑制TRAMP C2细胞的增殖和减弱ERK/MAPK和对FGF和IL-1/TNF响应的主要转录因子NF

Sci Rep:肝细胞生长因子激活抑制剂-2的Kunitz结构域I能够抑制蛋白裂解酶活性和人类前列腺癌细胞的侵入能力

细胞周围的蛋白水解的异常调节对肿瘤侵入和癌症恶化是需要的。有研究表明肝细胞生长因子激活抑制剂-2(HAI-2)表达的下调能够导致蛋白裂解酶的激活(一种膜锚定的丝氨酸蛋白酶)、人类前列腺癌细胞运动和肿瘤生长的促进。最近,有研究人员进一步鉴定了是否HAI-2是一个蛋白裂解酶的同源抑制剂,并且鉴定了HAI-2的哪一个结构域对抑制蛋白裂解酶和人类前列腺癌细胞运动是需要的。研究发现,HAI-2的超表达能够抑

Int J Mol Med:低剂量放射可以通过ATM/p21信号通路抑制人类p53null类型前列腺癌细胞的增殖

低剂量的电离辐射(LDIR)能够诱导毒物兴奋效应,并对正常哺乳动物细胞发挥出收养效应和刺激细胞增殖;然而,该影响在癌症细胞中却没有。并且,到目前为止对阐释正常细胞和癌细胞之间差异性的响应的分子机制所知甚少。最近,有研究人员阐释了人类前列腺癌细胞系PC-3和正常前列腺细胞系RWPE-1对LDIR表现出了不同的生物学响应。研究人员通过细胞周期分析发现,在PC-3细胞而不是RWPE-1细胞中,LDIR能

Cell Rep:一个前列腺癌风险元件具有抑制回路的功能,并调控HOXA13

前列腺癌(PCa)在美国是一种主导性的癌症,并且遗传因素在PCa敏感的患者中贡献率达到了大约42%。最近,有研究人员分析了一个位于7p15.2的PCa风险区域,从而尝试获得该非编码区域是通过怎样的机制来对基因进行调控的以及是怎样来形成前列腺癌风险的。研究人员进行了Hi-C分析并且阐释了该区域具有很长范围的与HOXA位点互作的区域,大约相距873kb。利用CRISPR/Cas9系统,研究人员敲除了一